#### Edgar Filing: HEMISPHERX BIOPHARMA INC - Form 4

HEMISPHERX Form 4 July 19, 2016	BIOPHARM	IA INC	0						
FORM 4	1								PPROVAL
	UNITED	STATES			AND EX 1, D.C. 20		E COMMISSION	N OMB Number:	3235-0287
Check this box if no longer subject to Section 16. SECURITIES SECURITIES								Estimated burden hou response	urs per
obligations may continue <i>See</i> Instruction 1(b).	e. Section 17	(a) of the I	Public U	Jtility Ho	lding Co		of 1935 or Section		
(Print or Type Resp	ponses)								
1. Name and Addr MITCHELL W	2. Issuer Name <b>and</b> Ticker or Trading Symbol HEMISPHERX BIOPHARMA INC [HEB]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last)	(First) (	Middle)	3. Date of Earliest TransactionX_ Director				109	% Owner	
THE ROKEBY AVE	7 #805, 3901	W END	(Month/Day/Year) — Officer (give title Other (specify below)						er (specify
	(Street) 4. If Amendment, Date Original Filed(Month/Day/Year)				Applicable Line) _X_ Form filed by	<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting</li> </ul>			
NASHVILLE,	TN 37205						Person	More than One K	eporting
(City)	(State)	(Zip)	Tab	ole I - Non-	Derivative	e Securities A	Acquired, Disposed	of, or Beneficia	lly Owned
	Fransaction Date onth/Day/Year)		Date, if	3. Transactic Code (Instr. 8)	4. Securit onAcquired Disposed (Instr. 3,	l (A) or l of (D)	Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code V	Amount	(D) Price	(Instr. 5 und 1)		
Reminder: Report	on a separate line	e for each cla	ass of sec	urities bene	-	-	-		
					inforr requi	nation con red to resp ays a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)
	Tab					sposed of, or convertible	Beneficially Owner securities)	đ	

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities

#### Edgar Filing: HEMISPHERX BIOPHARMA INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8)	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	(Month/Day/Y	ear)	(Instr. 3 and	4)
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Incentive Rights $(1)$	\$ 0	07/15/2016		А	12,671	01/15/2017	01/15/2017	Common Stock	12,671

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships					
	Director	10% Owner	Officer	Other		
MITCHELL WILLIAM M THE ROKEBY #805 3901 W END AVE NASHVILLE, TN 37205	Х					
Signaturos						

### Signatures

William M.	07/10/2016
Mitchell	07/19/2016

<u>\*\*</u>Signature of Reporting Person

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

Date

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Issued pursuant to the Hemispherx Biopharma Inc 2016 voluntary incentive stock award plan. Pursuant to the plan, the reporting person has elected to withhold a portion of their Director's fee in exchange for the incentive right. The incentive right grants the reporting person

(1) the right to receive a number of shares of common stock based upon the market price on the day prior to election. The incentive right automatically converts into common stock on the date exercisable. The plan is described in the Issuer's annual 10K report for the year ended 12/31/15.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.